Abstract: Objective The aim of this study was to investigate the therapeutic effect of isoglycyrrhizic acid magnesium in the treatment of patients with severe chronic hepatitis B (CHB) and the changes of peripheral blood regulatory T lymphocytes (Treg) and helper T cell 17 (Th17). Methods 80 patients with CHB of severe degree in our hospital from October 2017 through September 2018, and were divided into observation (n = 50) and control group (n = 30). They were given liver protection and antiviral treatment, and those in the observation group were treated withisoglycyrrhizic acid magnesium at base of treatment in the control. The regimen lasted for 30 days. Results At the end of 30 days of treatment, serum AST in the observation group was (124.2±10.2) U/L, significantly lower than [(179.3±13.5) U/L, P<0.05], serum ALT was (105.1±10.8) U/L, significantly lower than [(135.6±14.8) U/L),P<0.05], serum bilirubin level was (34.8±4.8)μmol/L, significantly lower than [(45.0±5.2)μmol/L,P<0.05] in the control; serum TNF-α in the observation group was (10.2±2.8) ng/L, which was significantly lower than [(13.5±2.5) ng /L, P<0.05], and the IL-4 was (49.1±7.2) ng/L, significantly lower than [(62.2±6.2) ng/L, P<0.05], serum IL-10 was (13.6±2.8) ng / L, significantly lower than [(19.3±3.2) ng/L,P<0.05] ], while serum IL-2 was (168.2±15.8) ng/L, which was significantly higher than [(142.2±14.0) ng/L,P<0.05] in the control; in the observation group, the percentage of peripheral blood Treg cells were (3.1±0.4)%, which was significantly lower than [(5.9±0.5)%,P <0.05], and the percentage of Th17 cells was (3.2±0.4)%, which was significantly lower than [( 4.9±0.5)%, P<0.05], and the ratio of Treg / Th17 cells was (0.9±0.1)%, significantly lower than [(1.2±0.3)%, P<0.05] in the control; the peripheral blood CD4⁺ cells in the observation group was (42.2±4.3)%, significantly higher than [(38.2±3.9)%, P<0.05], the CD8 ⁺ was (21.2±2.9)%, significantly lower than [(26.2±2.2)%, P<0.05], and the CD4 ⁺ / CD8 ⁺ cell ratio was (1.8±0.2), significantly higher than [(1.6±0.5), P<0.05] in the control; 90.0% of patients in the observation group improved, which was significantly higher than 70.0% in the control group (P<0.05). Conclusion The application of isoglycyrrhizic acid magnesium in patients with severe chronic hepatitis B has obvious curative effects, which might promote liver function recovery and correct immune dysfunction.

Key words: Chronic hepatitis B, Isoglycyrrhizic acid magnesium, Regulatory T lymphocytes, Helper T cell 17, T cell subsets, Therapy